Background
CLL14 was a phase III randomized open-label trial evaluating fixed-duration venetoclax (BCL-2 inhibitor) plus obinutuzumab (VenO) versus chlorambucil plus obinutuzumab (ClbO) in previously untreated CLL patients with coexisting conditions rendering them unfit for intensive chemoimmunotherapy (FCR). It tested whether a fixed 12-month BCL-2 inhibitor plus anti-CD20 regimen could improve upon the ClbO standard established in CLL11.
Interventions and follow up
Arm A: Chlorambucil 0.5 mg/kg + obinutuzumab 1000 mg ×12 cycles (28-day) [ClbO] (n=216)
Arm B: Venetoclax (5-week ramp-up to 400 mg daily) ×12 cycles + obinutuzumab cycles 1–6 (12 cycles total, fixed-duration) [VenO] (n=216)
Primary endpoint: Investigator-assessed PFS; secondary: MRD, OS, response rates, safety
mFollow up: 52.4 months (5-year update)
Arm B: Venetoclax (5-week ramp-up to 400 mg daily) ×12 cycles + obinutuzumab cycles 1–6 (12 cycles total, fixed-duration) [VenO] (n=216)
Primary endpoint: Investigator-assessed PFS; secondary: MRD, OS, response rates, safety
mFollow up: 52.4 months (5-year update)
Results
5-yr PFS: 35.4% (VenO) vs 12.0% (ClbO), HR 0.35, 95% CI 0.26–0.46, P<.0001
mPFS: 76.2 vs 36.4 months
Bone marrow MRD negativity (10⁻⁴) post-treatment: 57% vs 17%
5-yr OS: 81.9% vs 77.0% (not significant)
Subgroups: benefit consistent across del17p and IGHV-unmutated patients
mPFS: 76.2 vs 36.4 months
Bone marrow MRD negativity (10⁻⁴) post-treatment: 57% vs 17%
5-yr OS: 81.9% vs 77.0% (not significant)
Subgroups: benefit consistent across del17p and IGHV-unmutated patients
Adverse events
Hematologic (Grade ≥3, VenO vs ClbO): neutropenia 52.8% vs 48.1%; overall Grade ≥3 AEs 75.0% vs 70.3%
Infections: Grade ≥3 infections 17.5% vs 15.0%
Other: tumor lysis syndrome Grade ≥3 1.4% vs 3.3% (managed with TLS prophylaxis); atrial fibrillation ~3% both arms; second primary malignancies 7.4% vs 9.7%
Infections: Grade ≥3 infections 17.5% vs 15.0%
Other: tumor lysis syndrome Grade ≥3 1.4% vs 3.3% (managed with TLS prophylaxis); atrial fibrillation ~3% both arms; second primary malignancies 7.4% vs 9.7%
Conclusions
Fixed-duration venetoclax plus obinutuzumab significantly prolonged PFS (5-yr PFS 35% vs 12%, HR 0.35) and achieved substantially higher MRD-negativity rates versus chlorambucil-obinutuzumab in unfit/elderly CLL, establishing VenO as a preferred standard-of-care regimen and demonstrating durable benefit from a time-limited BCL-2 inhibitor-based regimen.
Key Limitations
OS not improved at 5 years (effective salvage/crossover) limits interpretation of long-term survival impact; ClbO comparator now considered suboptimal versus BTKi-based regimens; unfit population defined by CIRS/creatinine may not capture all comorbidity profiles; IGHV-unmutated and del17p/TP53-mutant patients had inferior outcomes despite benefit; no comparison to BTKi + venetoclax combinations (AMPLIFY, GAIA/CLL13); MRD endpoint (10⁻⁴) less sensitive than contemporary NGS-based 10⁻⁵/10⁻⁶ assays.
Clinical Context
CLL14 established venetoclax + obinutuzumab as the paradigm for fixed-duration BCL-2-based combination therapy in CLL, fundamentally changing the treatment landscape. FDA approved VenO for 1L CLL in May 2019. GAIA/CLL13 subsequently compared VenO, ibrutinib-based, and VenO+ibrutinib combinations in fit patients, while AMPLIFY tested acalabrutinib + venetoclax ± obinutuzumab. The 12-month fixed-duration principle is a major advantage over continuous BTKi therapy. ESMO and iwCLL guidance support VenO in unfit/elderly 1L CLL. Management of TLS risk during venetoclax ramp-up (hydration, uric-acid lowering, stepwise dose escalation) is essential.